BS_CZ3ER8DY
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 64.80000000000001
- os_event
- false
- age_years
- 1.312
- sex
- M
- race
- White
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.966775048
- umap2_2d
- 1.929919198
- umap1_3d
- 0.051724659
- umap2_3d
- 4.321223391
- umap3_3d
- -2.604113161
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- PROTEIN_SECRETION+0.560
- MYC_TARGETS_V1+0.490
- INTERFERON_GAMMA_RESPONSE+0.450
- MTORC1_SIGNALING+0.420
- E2F_TARGETS+0.410
- ANDROGEN_RESPONSE+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.320
- G2M_CHECKPOINT+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
Top 10 suppressed
- KRAS_SIGNALING_DN-0.330
- MYOGENESIS-0.330
- APICAL_SURFACE-0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- APICAL_JUNCTION-0.240
- ESTROGEN_RESPONSE_EARLY-0.240
- WNT_BETA_CATENIN_SIGNALING-0.240
- COAGULATION-0.210
- ESTROGEN_RESPONSE_LATE-0.190
- NOTCH_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CZ3ER8DY | Supratentorial Ependymoma | — | 0.928 |
| 2 | BS_W80TJC27 | EPN | Supratentorial EPN | 0.921 |
| 3 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.913 |
| 4 | BS_MT15SGJN | EPN | Supratentorial EPN | 0.905 |
| 5 | BS_MT15SGJN | Supratentorial Ependymoma | — | 0.892 |
| 6 | R427 | — | — | 0.885 |
| 7 | SJEPD030292_D1.RNA-Seq | EPN | Supratentorial EPN | 0.838 |
| 8 | MNG726 | — | — | 0.834 |
| 9 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.829 |
| 10 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.560 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |